$BIMI
BIMI Holdings Inc. Stock $bimi

$bimi Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022074244 Filed on November 21, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$11.83M	$7.315M	$13.78M
YoY Change	530.18%	-46.91%	345.87%
Cost Of Revenue	$9.880M	$5.730M	$11.75M
YoY Change	429.18%	-51.23%	315.14%
Gross Profit	$1.950M	$1.585M	$2.029M
YoY Change	19054.72%	-21.9%	680.42%
Gross Profit Margin	16.48%	21.66%	14.73%
Selling, General & Admin	$11.90M	$4.677M	$3.574M
YoY Change	274.18%	30.84%	111.51%
% of Gross Profit	610.4%	295.12%	176.16%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$58.32K	$39.46K	$60.35K
YoY Change	-10.24%	-34.61%	-79.88%
% of Gross Profit	2.99%	2.49%	2.97%
Operating Expenses	$11.90M	$4.677M	$3.574M
YoY Change	274.18%	30.84%	111.51%
Operating Profit	-$9.953M	-$3.092M	-$1.545M
YoY Change	213.89%	100.09%	8.07%
Interest Expense	-$176.4K	$97.37K	-$84.31K
YoY Change	75.57%	-215.49%	-75.2%
% of Operating Profit
Other Income/Expense, Net	-$6.108M	-$622.7K	-$74.30K
YoY Change	2207.68%	738.06%	-843.0%
Pretax Income	-$21.62M	-$3.715M	-$1.704M
YoY Change	-27.11%	118.01%	-3.73%
Income Tax	$6.090K	-$575.00	$5.930K
% Of Pretax Income
Net Earnings	-$22.39M	-$3.713M	-$1.703M
YoY Change	-24.53%	117.96%	-10.82%
Net Earnings / Revenue	-189.29%	-50.76%	-12.36%
Basic Earnings Per Share		-$0.16	-$0.06
Diluted Earnings Per Share	-$8.40	-$0.16	-$314.5K
COMMON SHARES
Basic Shares Outstanding	38.43M shares	22.86M shares	27.08M shares
Diluted Shares Outstanding		23.19M shares	27.08M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.337M	$1.047M	$209.8K
YoY Change	-51.3%	398.99%	-98.19%
Cash & Equivalents	$2.337M	$1.047M	$209.8K
Short-Term Investments
Other Short-Term Assets	$9.137M	$5.669M	$10.97M
YoY Change	92.41%	-48.32%	91.42%
Inventory	$7.654M	$1.230M	$2.117M
Prepaid Expenses
Receivables	$3.208M	$7.093M	$11.62M
Other Receivables	$899.9K	$2.346M	$1.386M
Total Short-Term Assets	$23.24M	$17.38M	$26.30M
YoY Change	9.81%	-33.91%	3.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.703M	$2.884M	$6.111M
YoY Change	-51.63%	-52.81%	618.96%
Goodwill	$2.066M	$8.376M
YoY Change	-75.34%
Intangibles	$16.18K	$15.87K
YoY Change	-10.29%
Long-Term Investments	$1.800M
YoY Change
Other Assets	$3.951M	$366.4K	$204.2K
YoY Change	1803.77%	79.44%	20.11%
Total Long-Term Assets	$12.48M	$15.62M	$36.78M
YoY Change	-26.46%	-57.53%	353.46%
TOTAL ASSETS
Total Short-Term Assets	$23.24M	$17.38M	$26.30M
Total Long-Term Assets	$12.48M	$15.62M	$36.78M
Total Assets	$35.71M	$33.00M	$63.08M
YoY Change	-6.33%	-47.68%	87.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.79M	$4.232M	$13.47M
YoY Change	46.96%	-68.58%	98.38%
Accrued Expenses	$3.078M	$3.176M	$1.617M
YoY Change	-0.16%	96.39%	127.79%
Deferred Revenue
YoY Change
Short-Term Debt	$818.4K	$1.383M	$5.975M
YoY Change	-54.52%	-76.86%	33.37%
Long-Term Debt Due	$106.0K	$183.2K	$0.00
YoY Change	-71.3%		-100.0%
Total Short-Term Liabilities	$25.36M	$18.90M	$24.19M
YoY Change	14.8%	-21.86%	20.82%
LONG-TERM LIABILITIES
Long-Term Debt	$314.8K	$475.0K	$794.5K
YoY Change	-41.49%	-40.21%	467.53%
Other Long-Term Liabilities	$4.820M	$3.419M	$3.309M
YoY Change	15.82%	3.32%
Total Long-Term Liabilities	$314.8K	$3.894M	$4.103M
YoY Change	-93.3%	-5.11%	2831.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.36M	$18.90M	$24.19M
Total Long-Term Liabilities	$314.8K	$3.894M	$4.103M
Total Liabilities	$30.50M	$22.79M	$28.55M
YoY Change	13.83%	-20.16%	40.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.14M
YoY Change	46.44%
Common Stock	$3.765K	$65.80M
YoY Change	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.048M	$9.798M	$34.53M
YoY Change
Total Liabilities & Shareholders Equity	$35.71M	$33.00M	$63.08M
YoY Change	-6.33%	-47.68%	87.9%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$22.39M	-$3.713M	-$1.703M
YoY Change	-24.53%	117.96%	-10.82%
Depreciation, Depletion And Amortization	$58.32K	$39.46K	$60.35K
YoY Change	-10.24%	-34.61%	-79.88%
Cash From Operating Activities	-$2.925M	-$8.285M	$1.042M
YoY Change	-329.93%	-895.47%	70.74%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	-$1.429M
YoY Change		-100.0%	1091.08%
Acquisitions	$2.768M
YoY Change
Other Investing Activities	-$356.9K	-$180.0K	-$87.53K
YoY Change	-402.0%	105.64%	-100.84%
Cash From Investing Activities	-$356.9K	-$180.0K	-$1.517M
YoY Change	-132.21%	-88.13%	-114.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.075M	4.690M	259.3K
YoY Change	150.7%	1708.6%	-156.37%
NET CHANGE
Cash From Operating Activities	-2.925M	-8.285M	1.042M
Cash From Investing Activities	-356.9K	-180.0K	-1.517M
Cash From Financing Activities	4.075M	4.690M	259.3K
Net Change In Cash	793.4K	-3.776M	-216.0K
YoY Change	-80.2%	1647.67%	-102.08%
FREE CASH FLOW
Cash From Operating Activities	-$2.925M	-$8.285M	$1.042M
Capital Expenditures		$0.00	-$1.429M
Free Cash Flow		-$8.285M	$2.471M
YoY Change		-435.31%	238.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma	-0.23
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	bimi	Issuance Of Common Share For Equity Acquisition Of Minkang Hospital IssuanceOfCommonShareForEquityAcquisitionOfMinkangHospital		usd
	bimi	Issuance Of Shares Of Common Stock For Prepayment Of Equity Acquisition Of Zhuoda IssuanceOfSharesOfCommonStockForPrepaymentOfEquityAcquisitionOfZhuoda		usd
	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices		usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Pharmacy Group IntangibleAssetsRecognizedFromEquityAcquisitionOfPharmacyGroup		usd
	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup		usd
	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital		usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Boqi Group IntangibleAssetsRecognizedFromEquityAcquisitionOfBoqiGroup		usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Boqi Group IntangibleAssetsRecognizedFromEquityAcquisitionOfBoqiGroup		usd
	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup		usd
	bimi	Outstanding Payment For Equity Acquisition Of Guanzan Group OutstandingPaymentForEquityAcquisitionOfGuanzanGroup		usd
	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda		usd
	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition		usd
	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals		usd
	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets		usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities		usd
	bimi	Addition During The Year AdditionDuringTheYear		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
CY2022Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss		usd
CY2022Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16816256	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22864269	shares
	us-gaap	Diluted Earnings Per Share Pro Forma DilutedEarningsPerShareProForma	-0.23
	us-gaap	Diluted Earnings Per Share Pro Forma DilutedEarningsPerShareProForma	-0.65
	bimi	Other Revenues OtherRevenues		usd
CY2022Q3	bimi	Other Unallocated Assets Phenix Bio Inc OtherUnallocatedAssetsPhenixBioInc		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50155
	dei	Entity Registrant Name EntityRegistrantName	BIMI International Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0563302
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9th Floor, Building 2
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Chongqing Corporation Avenue
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Yuzhong District
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chongqing
	dei	Entity Address Country EntityAddressCountry	CN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	400010
	dei	City Area Code CityAreaCode	(+86)
	dei	Local Phone Number LocalPhoneNumber	023-6310 7239
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	BIMI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38434761	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1046876	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4797849	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7092589	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7005442	usd
CY2022Q3	bimi	Advances To Suppliers AdvancesToSuppliers	4460024	usd
CY2021Q4	bimi	Advances To Suppliers AdvancesToSuppliers	3163836	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	343901	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	622554	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1230339	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2639883	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3210356	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2930083	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	17384085	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21159647	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	186382	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	207549	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2884120	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3521401	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15874	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18039	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3976697	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4845509	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	180000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	8376217	usd
CY2021Q4	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3082917	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8376217	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	15619290	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16968715	usd
CY2022Q3	us-gaap	Assets Assets	33003375	usd
CY2021Q4	us-gaap	Assets Assets	38128362	usd
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1382630	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1799394	usd
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	183203	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	369187	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	6320075	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5211160	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4231997	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7339210	usd
CY2022Q3	bimi	Advances From Customers AdvancesFromCustomers	1515458	usd
CY2021Q4	bimi	Advances From Customers AdvancesFromCustomers	1943028	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	475518	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	730285	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	390275	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	662777	usd
CY2022Q3	bimi	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3563059	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	836871	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	954182	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18899086	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22092140	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3418873	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4161789	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	475049	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	538006	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3893922	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4699795	usd
CY2022Q3	us-gaap	Liabilities Liabilities	22793008	usd
CY2021Q4	us-gaap	Liabilities Liabilities	26791935	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38434761	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38434761	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8502222	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8502222	shares
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65759712	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55220130	usd
CY2022Q3	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	2263857	usd
CY2021Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	2263857	usd
CY2022Q3	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	-58498042	usd
CY2021Q4	us-gaap	Retained Earnings Unappropriated RetainedEarningsUnappropriated	-47900929	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	234466	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1601870	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9798428	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11193430	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	411939	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	142997	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10210367	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11336427	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33003375	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38128362	usd
CY2022Q3	us-gaap	Revenues Revenues	7314842	usd
CY2021Q3	us-gaap	Revenues Revenues	13777494	usd
	us-gaap	Revenues Revenues	17261951	usd
	us-gaap	Revenues Revenues	25202485	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	5730125	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	11748385	usd
	us-gaap	Cost Of Revenue CostOfRevenue	12993304	usd
	us-gaap	Cost Of Revenue CostOfRevenue	20616279	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1584717	usd
	bimi	Bank Service Fees BankServiceFees	-60239	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4389	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3988	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-469720	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74302	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2270792	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-79595	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-622680	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	36417	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-158612	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2643119	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-302142	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3714808	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1703946	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10570841	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5238308	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-575	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5930	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30216	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37933	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3714233	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1709876	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10601057	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5276241	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3714233	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-1709876	usd
	us-gaap	Profit Loss ProfitLoss	-10601057	usd
	us-gaap	Profit Loss ProfitLoss	-5276241	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1450	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3712783	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1703432	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10597109	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5312658	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-399501	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-128005	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1367404	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-126893	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4113734	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1837881	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11968461	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5403134	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-487621	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6400	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5396789	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1022664	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6345	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3626113	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1831481	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23193842	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27084325	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16816256	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22864269	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11336427	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10569515	usd
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-11619777	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-75798	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10210367	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10601057	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5276241	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	165242	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	179147	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	35013	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-561	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	94037	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	585000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1108915	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1473306	usd
	bimi	Accounts Receivable AccountsReceivable	86586	usd
	bimi	Accounts Receivable AccountsReceivable	5028537	usd
	bimi	Increase Decrease In Advances To Supplier IncreaseDecreaseInAdvancesToSupplier	1693866	usd
	bimi	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	280273	usd
	bimi	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	-2464793	usd
	bimi	Inventories Inventories	-1409544	usd
	bimi	Inventories Inventories	1417149	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-868812	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3539872	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	-3107213	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	7617880	usd
	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	-427570	usd
	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	198399	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-860227	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	3966150	usd
	bimi	Increase Decreases In Accrued Taxes Payable IncreaseDecreasesInAccruedTaxesPayable	-272502	usd
	bimi	Increase Decreases In Accrued Taxes Payable IncreaseDecreasesInAccruedTaxesPayable	-119214	usd
	bimi	Other Payables And Accrued Liabilities OtherPayablesAndAccruedLiabilities	480142	usd
	bimi	Other Payables And Accrued Liabilities OtherPayablesAndAccruedLiabilities	-2086772	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7330007	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2547926	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	180000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1804536	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1804536	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	238955	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	73541	usd
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	248941	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4065000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	416764	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	34201	usd
	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	23886	usd
	bimi	Amount Financed From Related Parties AmountFinancedFromRelatedParties	171657	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4358181	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4514952	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-599147	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-83355	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3750973	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79135	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4797849	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	135309	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1046876	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	214444	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	245467	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	49037	usd
	us-gaap	Interest Paid Net InterestPaidNet	122539	usd
	us-gaap	Interest Paid Net InterestPaidNet	128973	usd
	us-gaap	Stock Issued1 StockIssued1	3818000	usd
	bimi	Issuance Of Common Share For Equity IssuanceOfCommonShareForEquity	3480000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3820000	usd
	bimi	Issuance Of Common Share For Equity Acquisition Of Minkang Hospital IssuanceOfCommonShareForEquityAcquisitionOfMinkangHospital	5930619	usd
	bimi	Issuance Of Shares Of Common Stock For Prepayment Of Equity Acquisition Of Zhuoda IssuanceOfSharesOfCommonStockForPrepaymentOfEquityAcquisitionOfZhuoda	1452000	usd
	bimi	Issuance Of Shares Of Common Stock For Payment Of Improvements To Offices IssuanceOfSharesOfCommonStockForPaymentOfImprovementsToOffices	696896	usd
	bimi	Intangible Assets Recognized From Equity Acquisition Of Pharmacy Group IntangibleAssetsRecognizedFromEquityAcquisitionOfPharmacyGroup	10443494	usd
	bimi	Goodwill Recognized From Equity Acquisition Of Guanzan Group GoodwillRecognizedFromEquityAcquisitionOfGuanzanGroup	7154392	usd
	bimi	Goodwill Recognized From Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospital GoodwillRecognizedFromEquityAcquisitionOfMinkangQiangshengAndEurasiaHospital	5930619	usd
	bimi	Outstanding Payment For Equity Acquisition Of Zhuoda OutstandingPaymentForEquityAcquisitionOfZhuoda	6100723	usd
	bimi	Outstanding Payment For Equity Acquisition OutstandingPaymentForEquityAcquisition	6100723	usd
	bimi	Outstanding Payment For Equity Acquisition Of Minkang Qiangsheng And Eurasia Hospitals OutstandingPaymentForEquityAcquisitionOfMinkangQiangshengAndEurasiaHospitals	9911416	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7797000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	738223	usd
	bimi	Common Stock To Be Issued Upon Conversion Of Convertible Promissory Notes CommonStockToBeIssuedUponConversionOfConvertiblePromissoryNotes	600	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORGANIZATION AND BUSINESS BACKGROUND</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BIMI International Medical, Inc. (the “Company” or “BIMI”) was incorporated in the State of Delaware as Galli Process, Inc. on October 31, 2000. On February 7, 2002, the Company changed its name to Global Broadcast Group, Inc. On November 12, 2004, the Company changed its name to Diagnostic Corporation of America. On March 15, 2007, the Company changed its name to NF Energy Saving Corporation of America, and on August 24, 2009, the Company changed its name to NF Energy Saving Corporation. On December 16, 2019, the Company changed its name to BOQI International Medical Inc., to reflect the Company’s refocus of its business from the energy saving industry to the health care industry. Since March 7, 2012, the common stock of the Company (the “Common Stock”) has been traded on the Nasdaq Capital Market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until October 14, 2019, the Company, through NF Energy Saving Investment Limited and its subsidiaries (the “NF Group”), operated in the energy saving enhancement technology industry in the People’s Republic of China (the “PRC”). The NF Group focused on providing services relating to energy saving technology, optimization design, energy saving reconstruction of pipeline networks and contractual energy management for the electric power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries in the PRC and the manufacture and sales of energy-saving flow control equipment. In late 2019, the Company committed to a plan to dispose of all its equity interests in the NF Group and on March 31, 2020, the Company entered into a stock purchase agreement (the “NF SPA”) to sell the NF Group. The sale of the NF Group closed on June 23, 2020. Please refer to NOTE 7 for more information relating to the sale of the NF Group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a Delaware holding company with operations conducted by its subsidiaries in China. The Company is now exclusively a healthcare products and services provider, offering a broad range of healthcare products and related services and operates five private hospitals in China. Due to our operations in China, our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in the PRC or changes in government relations between China and the United States or other governments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2019, the Company acquired 100% of the equity interests in Lasting Wisdom Holdings Limited (“Lasting”), a limited company incorporated under the laws of the British Virgin Islands (“BVI”). Lasting has limited operating activities since incorporation except for holding the ownership interest in Pukung Limited (“Pukung”), a company organized under the laws of Hong Kong. Pukung owns 100% of the equity interest in Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”), a company organized under the laws of the PRC. Xinrongxin owns all the ownership interest of Dalian Boqi Zhengji Pharmacy Chain Co., Ltd. (“Boqi Zhengji”). Boqi Zhengji operated 16 retail pharmacy stores in China at the time of the acquisition.. Xinrongxin also owns 100% equity interests in Dalian Boyi Technology Co., Ltd. (“Dalian Boyi”), a subsidiary established in January 2020 and responsible for the Company’s R&D and other technology related functions. On June 24, 2020, the Company established a wholly owned subsidiary Boyi (Liaoning) Technology Co.,Ltd (“Liaoning Boyi”), in order to be qualified to participate in local healthcare projects. On December 22, 2020, the Company established another subsidiary, Bimai Pharmaceutical (Chongqing) Co., Ltd., to replace Xinrongxin as the holding company owning all the retail, wholesale and hospital operations in China.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan holds an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, together with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., (‘Lijiantang”), a subsidiary established in May 2020. Lijiantang operates 4 retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”). The Lijiantang Pharmacy Group engages in the retail sale of medicine and other healthcare products to customers through its directly-owned stores. The Lijiantang Pharmacy Group offers a wide range of products, including prescription and over-the-counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji was closed by the end of 2020, although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021. On December 15, 2020, the Company entered into a stock purchase agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the Southeast region of China. The transaction closed on February 5, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2021, the Company entered into a stock purchase agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical services segment (“Bimi”). Bimi together with Guoyitang, Zhongshan, Qiangsheng , Eurasia and Minkang comprise the Company’s medical services group, which operate hospitals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021, the Company entered into a stock purchase agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). The closing of the Mali Hospital SPA is expected to take place in September 2022, subject to necessary regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders. The Company expects to seek stockholder approval of the sale at the upcoming annual meeting of stockholders. If approved and the Chairman’s Shares are issued, all obligations under the Chairman’s Note will have been performed and discharged in full without any payment of interest. The Company has no obligation to file a registration statement with the SEC for the resale of the Chairman’s Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">As of September 30,2022, the details of the Company’s major subsidiaries are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; border-bottom: black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place of incorporation and <br/> kind of legal entity</b></span></td> <td> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal activities and <br/> place of operation</b></span></td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective interest held</b></span></td> <td> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lasting Wisdom Holdings Limited (“Lasting”)</span></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">British Virgin Island, a limited liability company</span></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 27%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pukung Limited (“Pukung”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boyi (Liaoning) Technology Co., Ltd (“Liaoning Boyi”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT Technology service research and development</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dalian Boyi Technology Co., Ltd (“Dalian Boyi”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT Technology service research and development </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Guanzan Technology Co., Ltd. (“Guanzan”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of medical devices in the PRC</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Shude Pharmaceutical Co., Ltd.(“Shude”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Lijiantang Pharmaceutical Co., Ltd.(“Lijiantang”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bimai Pharmaceutical (Chongqing) Co., Ltd. </span></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 27%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment holding</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Guoyitang Hospital Co., Ltd. </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Huzhongtang Healthy Technology Co., Ltd. </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd. </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yunnan Yuxi Minkang Hospital Co., Ltd. </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wuzhou Qiangsheng Hospital Co., Ltd. </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suzhou Eurasia Hospital Co., Ltd.</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bimai Hospital Management (Chongqing) Co. Ltd </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital management in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pusheng Pharmaceutical Co., Ltd </span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Zhuoda Pharmaceutical Co., Ltd(“Zhuoda”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of generic drugs in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chongqing Qianmei Medical Devices Co., Ltd (“Qianmei”)</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The PRC, a limited liability company</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wholesale distribution of medical devices in the PRC</span></td> <td> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td> <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table>
CY2022Q3	bimi	Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement PercentageOfIncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement	0.13	pure
CY2022Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	7.0998	pure
CY2021Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	6.4854	pure
CY2022Q3	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.6068	pure
CY2021Q3	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.4714	pure
CY2021Q3	us-gaap	Gross Profit GrossProfit	2029109	usd
	us-gaap	Gross Profit GrossProfit	4268647	usd
	us-gaap	Gross Profit GrossProfit	4586206	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1104541	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1202387	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2563949	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2429401	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3572304	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2372056	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9632420	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7092971	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4676845	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3574443	usd
	us-gaap	Operating Expenses OperatingExpenses	12196369	usd
	us-gaap	Operating Expenses OperatingExpenses	9522372	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3092128	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1545334	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7927722	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4936166	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	293	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	616	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	97373	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	84310	usd
	us-gaap	Interest Expense InterestExpense	316692	usd
	us-gaap	Interest Expense InterestExpense	222547	usd
CY2022Q3	bimi	Bank Service Fees BankServiceFees	-60269	usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6444	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3948	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10945797	usd
CY2022Q2	bimi	Transfer Of Ownership Description TransferOfOwnershipDescription	On June 9, 2022, the Company entered into a stock purchase agreement the Chairman of the Board of the Company, Mr. Fnu Oudom, whereby Mr. Oudom agreed to purchase 12,500,000 shares of Common Stock for $5 million, or $0.40 per share (the “Chairman’s Shares”), subject to the approval of the stockholders of the Company. The purchase price per share reflects a 9% discount to the five-day average closing price of the Common Stock on NASDAQ before signing the SPA (the closing price of the Common Stock on Nasdaq on such date was $0.52). On June 9, 2022, Mr. Oudom provided the Company with $5 million as interim financing in consideration for the issuance of a $5 million subordinated promissory note (the “Chairman’s Note”), bearing no interest, which will become due and payable immediately if the sale of the Chairman’s Shares is not approved by the Company’s stockholders.
CY2022Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	10533868	usd
CY2021Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5276241	usd
CY2022Q3	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	59300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these condensed consolidated financial statements in conformity with the US GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities on the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Significant estimates and assumptions made by management include, among others, useful lives and impairment of long-lived assets, collectability of accounts receivable, advances to suppliers’ allowance for doubtful accounts, reserve of inventory, fair value of goodwill and valuation of derivative liabilities. While the Company believes that the estimates and assumptions used in the preparation of these condensed consolidated financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	288767	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	322145	usd
CY2022Q3	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	92655	usd
CY2021Q4	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	103178	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	26128171	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
CY2020Q4	bimi	Business Combination Consideration Transferred BusinessCombinationConsiderationTransferred	7374000	usd
CY2022Q3	us-gaap	Other Minority Interests OtherMinorityInterests	46295	usd
	bimi	Non Controlling Equity Interest Percentage NonControllingEquityInterestPercentage	0.20	pure
CY2021Q1	us-gaap	Cash Cash	28457	usd
CY2021Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	11797	usd
CY2021Q1	us-gaap	Supplies Supplies	12670	usd
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	41598	usd
CY2021Q1	us-gaap	Inventory Net InventoryNet	167440	usd
CY2021Q1	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	61102	usd
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	528814	usd
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	441150	usd
CY2021Q1	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent	7154393	usd
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	599391	usd
CY2021Q1	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	183796	usd
CY2021Q1	us-gaap	Disposal Group Including Discontinued Operation Accrued Income Taxes Payable DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable	121	usd
CY2021Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	231375	usd
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	161707	usd
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	354912	usd
CY2021Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	6916119	usd
	bimi	Heacquisitionoftheqiangshengeurasiaandminkanghospitals HEACQUISITIONOFTHEQIANGSHENGEURASIAANDMINKANGHOSPITALS	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td> <td style="width: 98%; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE ACQUISITION OF THE QIANGSHENG, EURASIA AND MINKANG HOSPITALS</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2021, the Company and Chongqing Bimai entered into a stock purchase agreement to acquire Qiangsheng, Eurasia and Minkang, three private hospitals in the PRC. Pursuant to the agreement, the Company agreed to purchase all the issued and outstanding equity interests in Qiangsheng, Eurasia and Minkang in consideration of approximately $25,023,555 (RMB162,000,000) to paid by the issuance of 800,000 shares of Common Stock, the value of which was agreed to be RMB 78 million or $12 million and the payment of RMB 84,000,000 (approximately $13,008,734) in cash. The first payment of RMB 20,000,000 (approximately $3,097,317) was made at the closing on May 6, 2021. The second and third payments of RMB 64,000,000 (approximately $9,911,416) were subject to post-closing adjustments based on the performance of the three hospitals in 2021 and 2022. The sellers had the right to receive the second and third payments in the form of the shares of Common Stock valued at $15.00 per share or in cash. As a result of the performance failure by the three hospitals for the year ended December 31, 2021, the sellers are not eligible to receive any contingent payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the identified assets acquired and liabilities assumed pursuant to the Qiangsheng, Eurasia and Minkang acquisitions as of May 6, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Items</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-indent: -9pt; padding-left: 0.25in">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,341</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivable, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,836</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Inventories, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,576</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances and other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,620</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Property, plant and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653,104</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,168,709</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 0.25in">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,067,529</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable, trade</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(355,980</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Advances from customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(36,798</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Taxes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(345,870</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other payables and accrued liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(311,174</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Lease liability-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365,788</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Lease liability-non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,988,195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total net assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,736,910</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all assets acquired, and liabilities assumed is the estimated book value of the Qiangsheng, Eurasia and Minkang hospitals. Goodwill represents the excess of the fair value of purchase price over the amounts assigned to the fair value of the assets acquired and the liabilities assumed of Qiangsheng, Eurasia and Minkang hospitals at the acquisition date.</p>
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	12341	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	41836	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	156576	usd
CY2022Q2	bimi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed I Amount Due From Related Parties Prepayments And Other Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIAmountDueFromRelatedPartiesPrepaymentsAndOtherReceivables	40620	usd
CY2022Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment	653104	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	2168709	usd
CY2022Q2	bimi	Goodwill1 Goodwill1	9067529	usd
CY2022Q2	bimi	Accounts Payable Trade1 AccountsPayableTrade1	-355980	usd
CY2022Q2	bimi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Payables And Accrued Liabilities Taxes Payable Advances From Customers BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherPayablesAndAccruedLiabilitiesTaxesPayableAdvancesFromCustomers	-36798	usd
CY2022Q2	bimi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Payables And Accrued Liabilities Taxes Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherPayablesAndAccruedLiabilitiesTaxesPayable	-345870	usd
CY2022Q2	bimi	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Payables And Accrued Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOtherPayablesAndAccruedLiabilities	-311174	usd
CY2022Q2	bimi	Lease Liabilitycurrent LeaseLiabilitycurrent	-365788	usd
CY2022Q2	bimi	Lease Liabilitynon Current LeaseLiabilitynonCurrent	-1988195	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	8736910	usd
CY2022Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7381356	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7327587	usd
	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-288767	usd
CY2021	bimi	Allowance For Doubtful Accounts AllowanceForDoubtfulAccounts	-322145	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7092589	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7005442	usd
CY2022Q3	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	561	usd
	us-gaap	Payments To Suppliers PaymentsToSuppliers	4460024	usd
CY2021	us-gaap	Payments To Suppliers PaymentsToSuppliers	3163836	usd
	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	4460024	usd
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	3163836	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	978440	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2395824	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	344554	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	347237	usd
CY2022Q3	bimi	Less Impairment Allowance LessImpairmentAllowance	92655	usd
CY2021Q4	bimi	Less Impairment Allowance LessImpairmentAllowance	103178	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1230339	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2639883	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	92655	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	103178	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	160711	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	63021	usd
CY2022Q3	us-gaap	Deposit Assets DepositAssets	14085	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	55052	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	293933	usd
	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	162272	usd
CY2022Q3	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	794444	usd
CY2021Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	1227778	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22127	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	1799346	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	766197	usd
CY2022Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	225739	usd
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	605234	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23420	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	26080	usd
CY2022Q3	us-gaap	Assets Designated To Closed Block Premiums And Other Receivables Net AssetsDesignatedToClosedBlockPremiumsAndOtherReceivablesNet	3210356	usd
CY2021Q4	us-gaap	Assets Designated To Closed Block Premiums And Other Receivables Net AssetsDesignatedToClosedBlockPremiumsAndOtherReceivablesNet	2930083	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6664766	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7442043	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3780646	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3920642	usd
CY2022Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	2884120	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	3521401	usd
	us-gaap	Depreciation Depreciation	157646	usd
	us-gaap	Depreciation Depreciation	175749	usd
CY2022Q3	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation	2886649	usd
CY2021Q4	us-gaap	Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation	3521401	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	19303	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	21495	usd
CY2022Q3	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-3429	usd
CY2021Q4	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-3456	usd
CY2022Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	15874	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	18039	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3429	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3456	usd
CY2021	bimi	Addition During The Year AdditionDuringTheYear	27590156	usd
CY2021	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	26128171	usd
CY2022Q3	bimi	Operating Lease OperatingLease	3976697	usd
CY2021Q4	bimi	Operating Lease OperatingLease	4845509	usd
CY2022Q3	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	3976697	usd
CY2021Q4	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	4845509	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	836871	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	954182	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3418873	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4161789	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4255744	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5115971	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	998042	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	895645	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	847209	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	779179	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	1753634	usd
	bimi	Total Minimum Lease Payments TotalMinimumLeasePayments	5273709	usd
	bimi	Less Amounts Representing Interest LessAmountsRepresentingInterest	-1017965	usd
CY2022Q3	bimi	Operating Lease Total OperatingLeaseTotal	4255744	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	6914232	usd
CY2022Q3	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
	us-gaap	Goodwill Transfers GoodwillTransfers	8376217	usd
CY2021	us-gaap	Goodwill Transfers GoodwillTransfers	8376217	usd
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1382630	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1799394	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	64005	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	16538	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	658252	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	907193	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	183203	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	369187	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	475049	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	538006	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	59003	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	60953	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	12.95
CY2022Q3	bimi	Shares Of Common Stock SharesOfCommonStock	130000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	5400000	usd
CY2021Q1	bimi	Shares Of Common Stock SharesOfCommonStock	152000	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	14.23
CY2021Q4	bimi	Accrued Operating Expenses AccruedOperatingExpenses	175215	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1121685	usd
CY2021Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	the “November SPA”) with the same two Institutional Investors to sell them a series of senior convertible notes (the “2021 Notes”) with an original issue discount of 20% and ranking senior to all outstanding and future indebtedness of the Company in a private placement. Each Institutional Investor paid $3,250,000 in cash for a 2021 Note in the face amount of $3,900,000. The November SPA also provided for the issuance of additional 2021 Notes in an aggregate original principal amount not to exceed $3,900,000 under certain circumstances. The November SPA also contains provisions about the Market Event Price. The 2021 Notes, which were issued on November 22, 2021, mature on the eighteen-month anniversary of the issuance date, are payable by the Company in installments and are convertible at the election of the Institutional Investors at the conversion price of $3.25 (post-Split Price and subject to the Event Market Price Adjustment), which is subject to adjustment in the event of default. Each Institutional Investor also received a warrant (the “Institutional Investor 2021 Warrant”) to purchase 180,000 shares of Common Stock at an initial exercise price of $3.55 per share (subject to the Event Market Price Adjustment). The placement agent for the private placement received a warrant (the “Placement Agent 2021 Warrant”, together with the Institutional Investor 2021 Warrant, the “2021 Warrants”) to purchase up to 8% of the aggregate number of shares of Common Stock in the private placement at an initial exercise price of $3.55 per share (post-Split Price and subject to the Event Market Price Adjustment), subject to increase based on the number of shares Common Stock issued pursuant to the 2021 Notes.
	bimi	Outstanding Balance For The Convertible Promissory Notes OutstandingBalanceForTheConvertiblePromissoryNotes	6320075	usd
CY2022Q3	bimi	Convertible Note Principal ConvertibleNotePrincipal	7800000	usd
CY2021Q4	bimi	Convertible Note Principal ConvertibleNotePrincipal	7800000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1479925	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2588840	usd
CY2022Q3	us-gaap	Convertible Debt ConvertibleDebt	6320075	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	5211160	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y5M1D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	686062	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	947911	usd
CY2022Q3	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	1653333	usd
CY2021Q4	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	1005832	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	730285	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	953959	usd
CY2022Q3	bimi	Longterm Payable LongtermPayable	102879	usd
CY2022Q3	bimi	Accrued Operating Expenses AccruedOperatingExpenses	-900	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16816256	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22864269	shares
	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma	-0.65
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3563059	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3082917	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	500000	usd
CY2021Q4	bimi	Employment Agreement Term EmploymentAgreementTerm	P1Y
CY2021Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000000	usd
CY2021Q4	us-gaap	Shares Issued SharesIssued	1000000	shares
CY2022Q2	us-gaap	Salaries And Wages SalariesAndWages	1000000	usd
CY2022Q2	us-gaap	Shares Issued SharesIssued	1000000	shares
CY2022Q2	us-gaap	Due To Employees Current And Noncurrent DueToEmployeesCurrentAndNoncurrent	300000	usd
CY2021Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	250000	usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	343901	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	622554	usd
CY2022Q3	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	2095518	usd
CY2021Q1	bimi	Aggregate Principal Amounts AggregatePrincipalAmounts	74473	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On February 2, 2022, we completed a five (5) for one (1) reverse stock split (the “Reverse Split”) of our issued and outstanding ordinary shares, par value $0.001 per share.
CY2022Q3	us-gaap	Shares Issued SharesIssued	12500000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10945797	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5396789	usd
CY2022Q3	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	41598014	usd
CY2022Q3	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-14524848	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	pure
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	pure
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17261951	usd
	bimi	Cost Of Revenues CostOfRevenues	12993304	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138944	usd
	bimi	Profitloss Profitloss	-10601059	usd
CY2022Q3	bimi	Total Assets TotalAssets	33003374	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	25202485	usd
	bimi	Cost Of Revenues CostOfRevenues	20616279	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	246335	usd
	bimi	Profitloss Profitloss	-5276241	usd
CY2021Q3	bimi	Total Assets TotalAssets	64286210	usd
	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	17813544	usd
	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	-551593	usd
	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	17261951	usd
	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	-2313821	usd
	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	-565433	usd
	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-1542248	usd
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	6179554	usd
	bimi	Total Net Loss TotalNetLoss	-10601057	usd
CY2022Q3	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	4087	usd
CY2022Q3	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	30070	usd
CY2022Q3	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	3762	usd
CY2022Q3	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	1142687	usd
CY2022Q3	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	4749603	usd
CY2022Q3	bimi	Total Consolidated Assets TotalConsolidatedAssets	33003375	usd
	bimi	Total Revenues From Reportable Segments TotalRevenuesFromReportableSegments	27424812	usd
	bimi	Other Revenues OtherRevenues	629198	usd
	bimi	Elimination Of Intersegments Revenues EliminationOfIntersegmentsRevenues	-2851525	usd
	bimi	Total Consolidated Revenues TotalConsolidatedRevenues	25202485	usd
	bimi	Total Loss From Reportable Segments TotalLossFromReportableSegments	-1303167	usd
	bimi	Elimination Of Intersegments Profit Or Loss EliminationOfIntersegmentsProfitOrLoss	-667910	usd
	bimi	Amortization Of Discount Of Notes And Convertible Notes AmortizationOfDiscountOfNotesAndConvertibleNotes	-2639374	usd
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	665790	usd
	bimi	Total Net Loss TotalNetLoss	-5276241	usd
CY2021Q3	bimi	Total Assets From Reportable Segments TotalAssetsFromReportableSegments	49176982	usd
CY2021Q3	bimi	Elimination Of Intersegments Receivables EliminationOfIntersegmentsReceivables	-14180718	usd
CY2021Q3	bimi	Other Unallocated Assets Xinrongxin OtherUnallocatedAssetsXinrongxin	12386406	usd
CY2021Q3	bimi	Other Unallocated Assets Liaoning Boyi OtherUnallocatedAssetsLiaoningBoyi	177335	usd
CY2021Q3	bimi	Other Unallocated Assets Dalian Boyi OtherUnallocatedAssetsDalianBoyi	21841	usd
CY2021Q3	bimi	Other Unallocated Assets Chongqing Bimai OtherUnallocatedAssetsChongqingBimai	12058313	usd
CY2021Q3	bimi	Other Unallocated Assets Bimi OtherUnallocatedAssetsBIMI	4646051	usd
CY2021Q3	bimi	Total Consolidated Assets TotalConsolidatedAssets	64286210	usd
	bimi	Schedule Of Revenues From Each Types Of Products Table Txet Block ScheduleOfRevenuesFromEachTypesOfProductsTableTxetBlock	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Medical devices wholesale</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,404,533</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,524,777</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Medical services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,282,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">6<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,694,510</span></div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Pharmaceutical wholesale</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,956,141</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,978,955</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Pharmacy retail</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">618,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">375,045</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">629,198</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,261,951</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,202,485</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	bimi	Total Revenue TotalRevenue	17261951	usd
	bimi	Total Revenue TotalRevenue	25202485	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
CY2021Q3	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.10	pure
	bimi	Accounts Receivable Percentage AccountsReceivablePercentage	0.3373	pure
CY2021Q3	us-gaap	Investment Sold Not Yet Purchased Percent Of Net Assets InvestmentSoldNotYetPurchasedPercentOfNetAssets	0.10	pure
CY2022Q3	us-gaap	Investment Sold Not Yet Purchased Percent Of Net Assets InvestmentSoldNotYetPurchasedPercentOfNetAssets	0.10	pure
CY2021Q4	us-gaap	Security Deposit SecurityDeposit		usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16816256	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27084325	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
	bimi	Appropriated Statutory Surplus Reserves AppropriatedStatutorySurplusReserves		usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	bimi	Increase Decrease In Advances To Supplier IncreaseDecreaseInAdvancesToSupplier	-4273327	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001213660

Files In Submission

Name	View Source	Status
bimi-20220930_lab.xml	Edgar Link	unprocessable
bimi-20220930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bimi-20220930_pre.xml	Edgar Link	unprocessable
bimi-20220930_def.xml	Edgar Link	unprocessable
0001213900-22-074244-index-headers.html	Edgar Link	pending
0001213900-22-074244-index.html	Edgar Link	pending
0001213900-22-074244.txt	Edgar Link	pending
0001213900-22-074244-xbrl.zip	Edgar Link	pending
bimi-20220930.xsd	Edgar Link	pending
f10q0922ex31-1_bimiintern.htm	Edgar Link	pending
f10q0922ex31-2_bimiintern.htm	Edgar Link	pending
f10q0922ex32-1_bimiintern.htm	Edgar Link	pending
f10q0922ex32-2_bimiintern.htm	Edgar Link	pending
f10q0922_bimiintern.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
f10q0922_bimiintern_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIMI
BIMI Holdings Inc. Stock $bimi

2022 Q4 Form 10-Q Financial Statement

#000121390022074244 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI BIMI Holdings Inc. Stock $bimi

2022 Q4 Form 10-Q Financial Statement

#000121390022074244 Filed on November 21, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI
BIMI Holdings Inc. Stock $bimi